Drug interactions
Dasatinib + Liposomal doxorubicin
Severity: Moderate
Dasatinib and Liposomal doxorubicin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Dasatinib is a weak-to-moderate CYP3A4 inhibitor and may modestly raise exposure to doxorubicin. Both drugs can also cause myelosuppression and cardiac effects, so overlapping toxicity is a practical concern.
What this interaction means in plain words
Dasatinib and Liposomal doxorubicin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Dasatinib belongs to Oncology; Liposomal doxorubicin belongs to Oncology.
Why it happens
Possible CYP3A4/P-glycoprotein inhibition by dasatinib plus additive myelosuppressive and cardiotoxic effects.
What to do
Monitor blood counts and cardiac function (LVEF) during combined therapy. Reduce the doxorubicin dose if excess toxicity appears.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dasatinib and Liposomal doxorubicin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Other interactions of Dasatinib
- Dasatinib + Saquinavir Contraindicated
- Dasatinib + Thioridazine Contraindicated
- Adagrasib + Dasatinib Major
- Amiodarone + Dasatinib Major
- Amisulpride + Dasatinib Major
- Amitriptyline + Dasatinib Major
Frequently asked questions
Can I take Dasatinib with Liposomal doxorubicin?
MediHelp rates the interaction as moderate. Dasatinib and Liposomal doxorubicin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Dasatinib is a weak-to-moderate CYP3A4 inhibitor and may modestly raise exposure to doxorubicin. Both drugs can also cause myelosuppression and cardiac effects, so overlapping toxicity is a practical concern.
How serious is the interaction between Dasatinib and Liposomal doxorubicin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and cardiac function (LVEF) during combined therapy. Reduce the doxorubicin dose if excess toxicity appears.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
